AVACTA GROUP PLC — Report Publication Announcement 2017

Mar 22, 2017

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 1169A

Avacta Group PLC

22 March 2017

22nd  March 2017

Avacta Group plc

("Avacta" or "the Group" or "the Company")

Avacta to present at the UK Investor Show

Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and research reagents, is pleased to announce that its Chief Executive, Alastair Smith, will be presenting at the UK Investor Show on 1s t April 2017  at the QE2 Centre, Westminster, London.  

The UK Investor Show is the largest UK stock market event with 3,000 investors expected to attend.

Members of Avacta Group's management team will be at stand 37 during the day and Alastair Smith will be presenting at 16:00 in the Winnifrith-Britten room.

For more information, including registration details, please visit:

www.ukinvestorshow.com

ENDS

Notes to Editors

For further information from Avacta Group plc, please contact:

Avacta Group plc Alastair Smith, Chief Executive Officer Tony Gardiner, Chief Financial Officer	Tel:  +44 (0) 844 414 0452 www.avacta.com
finnCap Ltd Geoff Nash / Giles Rolls - Nominated Adviser Tim Redfern / Alice Lane - Corporate Broking WG Partners David Wilson Nigel Barnes Claes Spang	Tel:  +44 (0) 207 220 0500 www.finncap.com Tel:  +44 (0) 203 705 9318 Tel:  +44 (0) 203 705 9217 www.wgpartners.co.uk
Zyme Communications (Trade and Regional Media) Katie Odgaard FTI Consulting (Financial Media and IR) Simon Conway / Natalie Garland-Collins	Tel: +44 (0)7787 502 947 katie.odgaard@zymecommunications.com  Tel: +44 (0) 203 727 1000 avacta@fticonsulting.com

About Avacta Group plc (www.avacta.com)

Avacta's principal focus is on its proprietary Affimer® technology which is a novel engineered alternative to antibodies that has wide application in Life Sciences for diagnostics, therapeutics and general research and development.

Antibodies dominate markets worth in excess of $50bn despite their shortcomings. Affimer technology has been designed to address many of these negative performance issues, principally; the time taken to generate new antibodies, the reliance on an animal's immune response, poor specificity in many cases, and batch to batch variability. Affimer technology is based on a small protein that can be quickly generated to bind with high specificity and affinity to a wide range of protein targets.

Avacta has a pre-clinical biotech development programme with an in-house focus on immuno-oncology and bleeding disorders as well as partnered development programmes. Avacta is also commercialising non-therapeutic Affimer reagents through licensing to developers of life sciences research tools and diagnostics.

This information is provided by RNS

The company news service from the London Stock Exchange

END

NRAFMGZFVMNGNZM